202 related articles for article (PubMed ID: 20136578)
21. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Xie F; Hopkins RB; Burke N; Habib M; Angelis CD; Pasetka M; Giotis A; Goeree R
Hosp Pract (1995); 2014 Apr; 42(2):38-45. PubMed ID: 24769783
[TBL] [Abstract][Full Text] [Related]
22. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
25. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Jensen AB; Wynne C; Ramirez G; He W; Song Y; Berd Y; Wang H; Mehta A; Lombardi A
Clin Breast Cancer; 2010 Dec; 10(6):452-8. PubMed ID: 21147688
[TBL] [Abstract][Full Text] [Related]
26. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
27. Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.
Jun JH
Korean J Ophthalmol; 2017 Aug; 31(4):368-369. PubMed ID: 28682020
[No Abstract] [Full Text] [Related]
28. Lip ulceration associated with intravenous administration of zoledronic acid: report of a case.
Andreadis D; Mauroudis S; Poulopoulos A; Markopoulos A; Epivatianos A
Head Neck Pathol; 2012 Jun; 6(2):275-8. PubMed ID: 22105344
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid in the treatment of metastatic breast cancer.
Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
31. Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Morris PG; Poznak CV; Modi S; Mak AF; Patil S; Larson S; Hudis CA; Divgi C; Grewal RK
Clin Breast Cancer; 2010 Feb; 10(1):33-9. PubMed ID: 20133256
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
34. Recommendations for zoledronic acid treatment of patients with bone metastases.
Berenson JR
Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
Lipton A
Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S14-20. PubMed ID: 17683649
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
[TBL] [Abstract][Full Text] [Related]
37. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid in metastatic bone disease: an audit based discussion.
Akbar RA; Gosh SK; Khalil S; ul Haq SM
J Ayub Med Coll Abbottabad; 2010; 22(3):5-7. PubMed ID: 22338405
[TBL] [Abstract][Full Text] [Related]
39. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.
Hatoum HT; Lin SJ; Smith MR; Guo A; Lipton A
Clin Breast Cancer; 2011 Jun; 11(3):177-83. PubMed ID: 21665138
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
Cha YJ; Lee YJ
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):274-82. PubMed ID: 23357846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]